Advanced prostate patients were treated with hormone injections only in the past. When these advanced cancer patients were no longer responding to those hormone injections, tablets such as Enzalutamide , Apalutamide and Abiraterone were added to the hormone injections.

A new combination has become available for use in these patients.

Data presented at the ESMO Congress 2024 (Barcelona, 13–17 September) demonstrated the potential of combining Enzalutamide and Radium 223 injections.

The combination Enzalutamide and Radium 223 injections was better than Enzalutamide tablets alone.

The combination is likely to become a standard of care for these patients.

The only caveat is that a lot of advanced cancer patients are nowadays treated with hormone injections and tablets upfront. This trial data does not directly apply to these patients.

Disclaimer: Please note – This blog is NOT medical advice. This blog is NOT a expert medical opinion on various topics. This blog is purely for information only and do check the sources where cited. Please DO consult your own doctor to discuss concerns and options relevant to you. The views expressed in this blog are NOT, in any way whatsoever, intended to be a substitute for professional advice. The blog is NOT previewed, commissioned or otherwise endorsed, in any way, by any organisation that the author is associated with. The views expressed in this blog likely represents some of the author’s personal views held at the time of drafting the blog and MAY CHANGE overtime, particularly when new evidence comes to light.